Clinical Trial Update: Mesenchymal Stem Cells for Frailty Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for mesenchymal stem cell therapy targeting frailty syndrome in Phase 1/Phase 2. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frailty Syndrome

Drugs mentioned

• Mesenchymal stem cell therapy (mesenchymal stem cells)

Snippet

Sponsor: Meribank Biotech Co., Ltd. | Conditions: Pathologic Processes | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING